Torrent Pharmaceuticals Limited has informed the Exchange regarding a press release dated February 13, 2026, titled "A Press Release on Financial Results which is being submitted to the media is also enclosedherewith".
TORNTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Torrent Pharmaceuticals reported its Q3 FY26 results on February 13, 2026. Consolidated revenue rose 18% year-on-year to ₹3,303 crores, driven by strong growth across India, Brazil and the US. Operating EBITDA grew 19% to ₹1,088 crores with margins steady at 33%. Net profit jumped 26% YoY to ₹635 crores, while gross margins held at 76%. For the first nine months of FY26, consolidated revenue was ₹9,783 crores (up 14%) and net profit was ₹1,774 crores (up 26%). The Board declared an interim dividend of ₹29 per share (580%), payable around March 6, 2026. The company also completed acquisition of a 48.8% controlling stake in JB Chemicals & Pharmaceuticals, and is pursuing a merger swap ratio of 51 Torrent shares for every 100 JB Pharma shares pending SEBI and NCLT approval.
Strong double-digit profit growth and a generous interim dividend are positive for shareholders. The completed JB Pharma acquisition and pending merger will significantly expand Torrent's scale and market position, though integration and merger approval risks remain. The full repayment of listed NCDs (₹143 crores) improves the debt profile.